GlassScriptPhysician profile
Jensen Volz
NPI 1043996713
$1,346.50
in general payments reported to CMS, 2019-2025
14 companies · $509 in 2025
The $509 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2024: $695 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $269.00 | 2024-2025 | Omvoh |
| Amgen INC. | $169.49 | 2024-2025 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $137.25 | 2024 | Hyqvia |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Nucala |
| Tg Therapeutics, INC. | $124.99 | 2025 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Pharmacosmos Therapeutics INC. | $124.98 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $60.55 | 2023-2025 | Tezspire, Fasenra, Saphnelo |
| Genentech USA, INC. | $53.39 | 2025 | Ocrevus Zunovo, Ocrevus |
| Abbvie INC. | $37.06 | 2024 | |
| Alnylam Pharmaceuticals INC. | $32.99 | 2024-2025 | Onpattro |
| Argenx US, INC. | $32.42 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Fresenius Kabi USA, LLC | $29.28 | 2024 | |
| Janssen Biotech, INC. | $25.11 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jensen Volz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.